Northport VA Medical Center, Northport, NY
Northport, New York, 11768-2200, United States
NCT Number: NCT06766331
Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans. Treatment of OUD with medication assisted therapy is highly effective, however this often occurs independently of infectious diseases care. This project will test out a new model that combines infectious diseases and OUD care within one VA clinic appointment. This new care model may improve the health of Veterans and reduce cost and time required for Veterans who often need to attend multiple outpatient appointments.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Northport, New York, 11768-2200, United States
Opioid use disorder (OUD) is associated with increased risk for overdose as well as acquisition and transmission of infectious diseases (ID), including HIV, hepatitis C virus (HCV), and bacterial sexually transmitted infections (STI). Previous studies support improved clinical outcomes when integrating treatment for OUD and screening and treatment of HIV and HCV in non-Veteran populations. However, clinical care for Veterans with OUD often requires appointments with multiple different healthcare providers. These care silos place an increased burden on this patient population who often have barriers to appointment attendance. Improved integration OUD and ID clinical care is needed. In a recent study of Veterans with OUD who accessed care at the Northport VA (Long Island, NY) the investigators identified 216 (43%) Veterans who had a history of injecting drug use and of those, 134 (62%) had HCV and 30 (13.9%) had at least one severe injection related infection requiring hospitalization. The investigators also found low rates of screening for bacterial sexually transmitted infections, including syphilis (n=371, 74%), gonorrhea (n=160, 31.9%), chlamydia (n=169, 33.7%) and low uptake of HIV pre-exposure prophylaxis (PrEP) (n=4, 0.8%). In this pilot study, the investigators will assess the feasibility and acceptability of an integrated ID screening and PrEP intervention for Veterans with OUD who are engaged in care through the Northport VA SUD clinic. The investigators will randomize Veterans to receive either integrated care (HIV, HCV, STI screening and/or PrEP plus SUD care) or treatment as usual (SUD care plus ID clinic referral). The investigators will also compare rates of HIV, HCV and bacterial STI screening as well as PrEP uptake between the groups. This research will benefit male and female Veterans with OUD. This project will be carried out at the Northport Veterans Affairs Medical Center (NVAMC). Information obtained from this study will be utilized to inform a larger multi-site VA trial assessing the efficacy of IC versus usual care.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Receipt of infectious diseases laboratory testing and/or PrEP for HIV within a single substance use disorder clinic appointment.
Time frame: 90 days
Proportion of Veterans who completed any screening for HIV, hepatitis C virus (HCV), gonorrhea, chlamydia, or syphilis during the intervention period
Time frame: 90 days
Proportion who initiated PrEP for HIV during the intervention period
Time frame: 90 days
Proportion who completed screening for HIV during the intervention period
Time frame: 90 days
Proportion who completed screening for HCV during the intervention period
Time frame: 90 days
Proportion who completed screening for gonorrhea during the intervention period
Time frame: 90 days
Proportion who completed screening for chlamydia during the intervention period
Time frame: 90 days
Proportion who completed screening for syphilis during the intervention period
Time frame: 270 days
Proportion who initiated PrEP for HIV at any point during the follow-up period
Time frame: 270 days
Proportion who completed screening for HIV at any point during the follow-up period
Time frame: 270 days
Proportion who completed screening for HCV at any point during the follow-up period
Time frame: 270 days
Proportion who completed screening for gonorrhea at any point during the follow-up period
Time frame: 270 days
Proportion who completed screening for chlamydia at any point during the follow-up period
Time frame: 270 days
Proportion who completed screening for syphilis at any point during the follow-up period
Time frame: 90 days
Proportion of Veterans who adhered to the PrEP prescription during the intervention period
Time frame: 270 days
Proportion of Veterans who adhered to the PrEP prescription during the follow-up period
Time frame: 90 days
Proportion of Veterans who agreed that the integrated care intervention was a feasible care model for the substance use disorder clinic
Time frame: 90 days
Proportion of Veterans who agreed that the integrated care intervention was an acceptable care model for the substance use disorder clinic
Contact information is provided by the study sponsor or research team.
VA Office of Research and Development
Fed
Integrating Infectious Diseases Screening and Treatment With Medication Assisted Therapy for Veterans With Opioid Use Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06187064
Bacterial Infections, Bacterial Infections and Mycoses
Seattle, Washington, United States
View Trial DetailsNCT05108935
Acquired Immunodeficiency Syndrome, Behavior
Durham, North Carolina, United States
View Trial DetailsNCT07631559
Behavior, Blood-Borne Infections
San Francisco, California, United States
View Trial DetailsNCT06799702
Blood-Borne Infections, Chemically-Induced Disorders
Colbert, Georgia, United States
View Trial Details